Abstract:e16591 Background: The current standard of care for MIBC is neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy (RC). However, more than 40% patients are ineligible for cisplatin-based chemotherapy. The adverse reactions, comorbidities and high recurrence rate also limited the implementation of neoadjuvant cisplatin-based chemotherapy. The combination application in perioperative of RC48-ADC and PD-1/CTLA-4 antibody may have synergistic anti-tumor effects and achieve more clinical benefit. Methods: This single arm, open-label, multicenter study evaluates the effectiveness and safety of disitamab vedotin (RC48-ADC), a humanized anti-HER2 antibody conjugated with monomethyl auristatin E, plus cadonilimab (AK104, PD-1/CTLA-4 bispecific antibody) as a novel neoadjuvant and adjuvant therapy in patients (pts) with treatment-naïve HER2-expressing (Immunohistochemistry, IHC 1+, 2+, 3+) MIBC (T2-T4a, N0-1, M0; ECOG PS score 0-1). Eligible pts received neoadjuvant RC48-ADC (2.0 mg/kg D1 Q2W, 4 cycles) + AK104 (6.0 mg/kg D1 Q2W, 4 cycles) followed by RC and RC48-ADC (2.0 mg/kg D1 Q3W, 6 cycles) + AK104 (10.0 mg/kg D1 Q3W, 14 cycles) of adjuvant treatment post-surgery. The primary end point was pathologic complete response (pCR, pT0N0M0). Secondary end points were pathologic downstaging rate, disease-free survival, overall survival, objective response rate, and safety. Results: As of January 2024, 18 (16 males, 2 Females) out of the planned 36 pts have been enrolled in the study with median age of 65.5 (44-80) years. HER2 expression was positive (IHC 2+ or 3+) in 84.6% pts, and PD-L1 positive (CPS ≥ 10) in 50%. Five pts had completed neoadjuvant therapy, and 2 pts (2/5) achieved partial response (PR), while 3 (3/5) stable disease (SD), with 100% (5/5) disease control rate (DCR). Four pts underwent RC and 1 refused, all 4 pts (100%) were pathologic downstaging to ≤ypT1N0M0, and 2 of them (2/4, 50%) achieved pCR who were both assessed as SD by imaging techniques before. The most common TRAEs in 14 pts who had undergone more than 1 cycle treatment was pruritus (35.7%). Two cases of Grade ≥3 TRAEs were observed (14.3%), a patient bearing background disease of hypertension experienced grade 4 myocarditis, and another patient with underlying renal insufficiency experienced grade 3 diarrhea. Conclusions: This is the first study to evaluate the effectiveness and safety in perioperative of HER2 targeting ADC plus PD-1/CTLA-4 bispecific antibody in HER2-expressing MIBCs. And neoadjuvant RC48-ADC combined with AK104 showed promising anti-tumor activity with high pCR rate and well tolerance in MIBC pts. More specific pathological assessment results and long-term survival data post adjuvant therapy are worth anticipating. Clinical trial information: NCT06074484 .

Identification of Chemotherapeutic Dihydromyricetin with Enhanced Anti-tumor Activity and Biosafety for Muscle Invasive Bladder Cancer

Disitamab vedotin alone or in combination with immune checkpoint inhibitors in bladder-sparing treatment of muscle-invasive bladder cancer: a real-world study

2002P Efficacy and Biomarker Analysis of Neoadjuvant Disitamab Vedotin Combined Immunotherapy in Patients with Muscle-Invasive Bladder Cancer: A Multi-Center Real-World Study

Homologous Targeting and Adhesion Abilities of Cellular Microvesicles for Enhanced Intravesical Therapy of Bladder Cancer

Preliminary results from a phase II study to evaluate the efficacy and safety of perioperative disitamab vedotin (RC48-ADC) plus cadonilimab (AK104, PD-1/CTLA-4 bispecific antibody) for HER2-expressing muscle-invasive bladder cancer (MIBC).

Pre-instillation of Tumor Microparticles Enhances Intravesical Chemotherapy of Nonmuscle-Invasive Bladder Cancer Through a Lysosomal Pathway.

Dihydromyricetin Inhibited the Proliferation of Human Bladder Cancer Cells and Its Mechanism

Enhanced Sensitivity to Mitomycin C by Abating Heat Shock Protein 70 Expression in Human Bladder Cancer Cell Line of BIU-87.

Efficacy and safety analysis of neoadjuvant chemotherapy combined with immunotherapy in patients with muscle-invasive bladder cancer

Neoadjuvant Therapy with Disitamab Vedotin in Treating Muscle-Invasive Bladder Cancer: A Case Report

In vivo bladder cancer growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002)

DPPG2-based thermosensitive liposomes as drug delivery system for effective muscle-invasive bladder cancer treatment in vivo

Metformin-Loaded Chitosan Hydrogels Suppress Bladder Tumor Growth in an Orthotopic Mouse Model via Intravesical Administration

Anti-tumor Effects and Cell Motility Inhibition of the DN604-gemcitabine Combined Treatment in Human Bladder Cancer Models.

Discovery of a potential bladder cancer inhibitor CHNQD-01281 by regulating EGFR and promoting infiltration of cytotoxic T cells

Targeting XBP1-mediated Β-Catenin Expression Associated with Bladder Cancer with Newly Synthetic Oridonin Analogues.

Real-world study of chemotherapy plus immunotherapy versus chemotherapy alone as neoadjuvant treatment guided bladder-sparing therapy for localized muscle-invasive bladder cancer.

Hsa-miR-30a-3p overcomes the acquired protective autophagy of bladder cancer in chemotherapy and suppresses tumor growth and muscle invasion

Single-Cell Sequencing Reveals that DBI is the Key Gene and Potential Therapeutic Target in Quiescent Bladder Cancer Stem Cells

MHP-1 Inhibits Cancer Metastasis and Restores Topotecan Sensitivity Via Regulating Epithelial-Mesenchymal Transition and TGF-β Signaling in Human Breast Cancer Cells.

Present Status, Challenges, and Prospects of Dihydromyricetin in the Battle against Cancer